LadRx Corporation
0.8000+0.00 (+0%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · LADX · USD
Key Stats
Market Cap
396.07KP/E (TTM)
-Basic EPS (TTM)
-5.04Dividend Yield
0%Recent Filings
8-K
LADRX enters creditor liquidation
LADRX Corporation executed a General Assignment for the Benefit of Creditors on July 28, 2025, handing over all assets to an assignee to settle creditor claims under California law. This liquidation event halted all operations, triggered immediate repayment demands on outstanding debts, and prompted resignations from key leaders including CEO Stephen Snowdy and CFO John Caloz. Creditors now await distributions amid uncertainties in asset administration.
8-K
LadRx halts aldoxorubicin approval push
LadRx Corporation announced on December 11, 2024, plans to propose using existing clinical data plus supplemental non-clinical data for FDA marketing approval of aldoxorubicin via the 505(b)(2) pathway. Yet management now believes approval is feasible but lacks resources to pursue required activities. This pivot signals funding constraints. No timeline or costs disclosed.
10-Q
Q1 FY2025 results
LadRx posted a $0.7 million net loss for Q1 2025 ended March 31, up slightly from $0.8 million a year earlier, driven by lower general and administrative expenses of $691K versus $802K while research and development dipped to $29K from $30K; no revenue emerged, unlike last year's $1 million milestone boost from XOMA deals. Operating loss narrowed to $720K from $832K, but net swung negative without that one-off, with EPS at -$1.45 on 495,092 diluted shares matching the basic count—no anti-dilution here. Cash drained $553K in operations to $207K quarter-end, deepening the $2.1 million working capital deficit amid zero capex or financing. Stock comp added $4K to costs. Yet funding hunt persists for LADR tech revival. Litigation drags on cooperation breaches.
8-K
Board member resigns cleanly
10-K
FY2024 results
LadRx Corporation reported a net loss of $1.6 million for FY2024 ended December 31, 2024, an improvement from the $3.8 million operating loss in FY2023, driven by $2 million in milestone payments from the XOMA royalty agreement for arimoclomol's FDA acceptance and first commercial sale, while research and development expenses rose to $0.8 million from $0.3 million amid efforts to advance aldoxorubicin toward NDA submission via the 505(b)(2) pathway. Q4 2024 saw $1 million in milestone revenue from arimoclomol's commercial launch, providing sequential cash momentum over Q3's quieter period, though general and administrative costs held steady at $2.8 million annually. With cash at $0.8 million, liquidity remains tight, underscoring the need for $1.5 million to initiate pre-NDA activities and $4 million more for full approval, absent which operations could stall. No dividends or buybacks occurred, but the company eyes partnered funding for LADR-7 trials. Regulatory hurdles in oncology approvals pose a key risk to quarterly progress.
ALXO
ALX Oncology Holdings Inc.
1.59+0.05
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CTMX
CytomX Therapeutics, Inc.
3.26-0.06
GRTX
Galera Therapeutics, Inc.
0.03+0.00
INBX
Inhibrx Biosciences, Inc.
77.05+8.56
LIXT
Lixte Biotechnology Holdings, I
4.35+0.07
RADX
Radiopharm Theranostics Limited
5.01-0.05
RNXT
RenovoRx, Inc.
1.05-0.08
SLXN
Silexion Therapeutics Corp
3.44+0.01
VINC
Vincerx Pharma, Inc.
0.03+0.00